Innovent Biologics, Inc. (OTCMKTS:IVBXF – Get Free Report) shares dropped 3.7% during trading on Tuesday . The stock traded as low as $4.43 and last traded at $4.43. Approximately 800 shares were traded during mid-day trading, a decline of 100% from the average daily volume of 237,210 shares. The stock had previously closed at $4.60.
Innovent Biologics Price Performance
The company has a 50 day moving average price of $4.94 and a 200 day moving average price of $5.15.
Innovent Biologics Company Profile
Innovent Biologics, Inc, a biopharmaceutical company, develops and commercializes monoclonal antibodies and other drug assets in the fields of oncology, ophthalmology, autoimmune, and cardiovascular and metabolic diseases in the People's Republic of China. It offers Tyvyt, a human anti-PD-1 monoclonal antibody; BYVASDA, a fully-human anti-VEGF monoclonal antibody; HALPRYZA, a recombinant chimeric murine/human anti-CD20 monoclonal antibody; SULINNO, a fully-human antiTNF-a monoclonal antibody; Pemazyre, a selective FGFR inhibitor; Olverembatinib, a novel BCR-ABL TK; Cyramza, a VEGF receptor 2 antagonist; and Retsevmo, a selective and potent RET kinase inhibitor.
Featured Stories
- Five stocks we like better than Innovent Biologics
- How to Calculate Inflation Rate
- Silicon Motion Proves That AI in Motion Stays in Motion
- How to Calculate Stock Profit
- Undervalued UnitedHealth Group Won’t Be For Long
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- The 5 Stocks Most Sold By Insiders This Year
Receive News & Ratings for Innovent Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innovent Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
